Literature DB >> 23288202

Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.

Haneen A Al-Mazroua1, Nawal M Al-Rasheed, Hesham M Korashy.   

Abstract

The incidence, prevalence, and hospitalization rates associated with heart failure (HF) are projected to increase substantially in the world. Among all medications used clinically to treat HF, valsartan (VAL) and spironolactone (SPL) have been shown to reduce morbidity and mortality. Recently, a novel cardiac gene cardiotrophin-1 (CT-1) has been shown to play a crucial role in the pathogenesis of HF. However, the ability of VAL and SPL to modulate the expression of CT-1 has not been investigated yet. Therefore, healthy and isoproterenol (ISO)-induced hypertrophy adult male Wistar albino rats were treated with either VAL or SPL for 14 days. Thereafter, cardiac markers of cardiotoxicity and hypertrophy, creatine kinase, heart weight/body weight ratio, and atrial natriuretic peptide mRNA levels were measured. In addition, CT-1 mRNA and protein levels were determined by real-time polymerase chain reaction and Western blot analysis. Our results showed that the increases in all HF markers, creatine kinase, heart weight/body weight ratio, and atrial natriuretic peptide mRNA levels in ISO-treated rats were significantly restored to their normal levels by VAL and SPL. In addition, induction of cardiac hypertrophy by ISO caused remarkable induction in CT-1 mRNA and protein expression levels by approximately 3.5- and 3-fold, respectively. Importantly, VAL and SPL significantly decreased the induction of CT-1 gene at the mRNA and protein levels in heart hypertrophied rats. On the other hand, treatment of cardiac-derived rat myoblast H9c2 cells with VAL and SPL significantly decreased angiotensin II-induced CT-1 mRNA levels through transcriptional mechanism, as demonstrated by the effect of transcription inhibitor, actinomycin D. In conclusion, VAL and SPL exhibited their cardioprotective effect through inhibiting the expression of CT-1 gene in cardiac hypertrophied rats.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23288202     DOI: 10.1097/FJC.0b013e318283a565

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.

Authors:  Toru Miyoshi; Kazufumi Nakamura; Daiji Miura; Masashi Yoshida; Yukihiro Saito; Satoshi Akagi; Yuko Ohno; Megumi Kondo; Hiroshi Ito
Journal:  Cardiol J       Date:  2018-05-02       Impact factor: 2.737

2.  Valsartan Upregulates Kir2.1 in Rats Suffering from Myocardial Infarction via Casein Kinase 2.

Authors:  Xinran Li; Hesheng Hu; Ye Wang; Mei Xue; Xiaolu Li; Wenjuan Cheng; Yongli Xuan; Jie Yin; Na Yang; Suhua Yan
Journal:  Cardiovasc Drugs Ther       Date:  2015-06       Impact factor: 3.727

3.  Circulating biomarker responses to medical management vs. mechanical circulatory support in severe inotrope-dependent acute heart failure.

Authors:  Anna J Meredith; Darlene L Y Dai; Virginia Chen; Zsuzsanna Hollander; Raymond Ng; Annemarie Kaan; Scott Tebbutt; Krishnan Ramanathan; Anson Cheung; Bruce M McManus
Journal:  ESC Heart Fail       Date:  2015-11-24

Review 4.  Regulation of Myocardial Extracellular Matrix Dynamic Changes in Myocardial Infarction and Postinfarct Remodeling.

Authors:  Alexey Ushakov; Vera Ivanchenko; Alina Gagarina
Journal:  Curr Cardiol Rev       Date:  2020

5.  Huoxue Qianyang Qutan recipe attenuates cardiac fibrosis by inhibiting the NLRP3 inflammasome signalling pathway in obese hypertensive rats.

Authors:  Bo Lu; Jun Xie; Deyu Fu; Xiaozhe Chen; Mingyi Zhao; Mingtai Gui; Lei Yao; Xunjie Zhou; Jianhua Li
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.